A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia (NCT07459647)
An Open-Label Study to Assess the Long-Term Safety, Tolerability, and Effectiveness of ML-007C-MA in Adult Participants With Schizophrenia
🩺 Plain-English Summary (8th-Grade Level)
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Who can join: Review the eligibility criteria below.
Location: Clinical Site — Little Rock, Arkansas
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- Clinical Site — Little Rock, Arkansas
- Clinical Site — Little Rock, Arkansas
- Clinical Site — Rogers, Arkansas
- Clinical Site — Bellflower, California
- Clinical Site — Cerritos, California
- Clinical Site — Culver City, California
- Clinical Site — Garden Grove, California
- Clinical Site — Lemon Grove, California
- Clinical Site — Long Beach, California
- Clinical Site — Los Angeles, California
- Clinical Site — Montclair, California
- Clinical Site — Oceanside, California
- Clinical Site — Orange, California
- Clinical Site — Pico Rivera, California
- Clinical Site — Riverside, California
- Clinical Site — San Diego, California
- Clinical Site — Sherman Oaks, California
- Clinical Site — Torrance, California
- Clinical Site — Hollywood, Florida
- Clinical Site — Hollywood, Florida
- Clinical Site — Miami, Florida
- Clinical Site — Miami Lakes, Florida
- Clinical Site — West Palm Beach, Florida
- Clinical Site — Atlanta, Georgia
- Clinical Site — Decatur, Georgia
📞 Contact the Study Coordinator
Phone: (650) 839-4385
Email: ML-007C-MA-SCZ@maplightrx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.